

**Edition 2010**

# **ESC GUIDELINES DESK REFERENCE**

**ESC Committee for Practice Guidelines**

**To improve the quality of clinical practice and patient care in Europe**

## **CARDIOVASCULAR MEDICINE**



## **COMPENDIUM OF ABRIDGED ESC GUIDELINES 2010**

**For more information**

**[www.escardio.org/guidelines](http://www.escardio.org/guidelines)**



**EUROPEAN  
SOCIETY OF  
CARDIOLOGY®**

# Compendium of Abridged ESC Guidelines 2010

768353

UNIVERSITATEA DE STAT DE MEDICINĂ ȘI FARMACIE  
„NICOLAE TESTEMIȚANU”  
BIBLIOTECA  
ȘTIINȚIFICĂ MEDICALĂ

SL2



Springer Healthcare

# CONTENTS

Preface .....	XI
Alec Vahanian	
Foreword .....	XIII
Roberto Ferrari	
Guidelines overview .....	XV

---

## Section I: Prevention of Cardiovascular Disease ..... 1

---

1. Cardiovascular Disease Prevention in Clinical Practice .....	3
The European Heart Health Charter and the Guidelines on Cardiovascular Disease Prevention .....	3
Why develop a preventive strategy in clinical practice? .....	5
What are the objectives of these guidelines? .....	5
People who stay healthy tend to have certain characteristics .....	5
What are the priorities for CVD prevention in clinical practice? .....	5
What are the objectives of CVD prevention? .....	6
When do I assess cardiovascular risk? .....	6
Why do the Guidelines stress the assessment of total CVD risk? .....	6
How do I assess CVD risk quickly and easily? .....	7
Assessing cardiovascular risk: What are the components? .....	7
How do I use the SCORE charts to assess CVD risk in asymptomatic persons? .....	7
Risk estimation using SCORE: Qualifiers .....	8
10 year risk of fatal CVD in high risk regions of Europe .....	8
10 year risk of fatal CVD in low risk regions of Europe .....	9
Relative risk chart .....	9
How do I manage the components of total CVD risk? .....	9
Total risk CVD management: A key message .....	10
Managing total cardiovascular risk .....	10
Why do people find it hard to change their life? .....	10
When to prescribe cardio-protective drugs in addition to those used to treat blood pressure, lipids and diabetes? .....	13
Why screen close relatives? .....	13
What would make the practice of CVD prevention easier? .....	13

---

## Section II: Hypertension ..... 15

---

1. The Management of Arterial Hypertension .....	17
Arterial hypertension .....	17
Total cardiovascular (CV) risk .....	18
Stratification of total CV risk .....	18
Clinical variables that should be used to stratify total CV risk .....	19
Diagnostic evaluation .....	20
Blood pressure (BP) measurement .....	20
Ambulatory and home BP measurements .....	20
Diagnostic evaluation: medical history and physical examination .....	21
Laboratory investigation .....	21
Searching for subclinical organ damage .....	22
Evidence on the benefit of antihypertensive treatment .....	22
Initiation of BP lowering therapy .....	23
Goals of treatment .....	23
Lifestyle changes .....	24
Choice of antihypertensive drugs .....	24
Conditions favouring the use of some antihypertensive drugs versus others .....	25
Contra-indications to use certain antihypertensive drugs .....	25
Monotherapy versus combination therapy .....	26
Possible combinations between some classes of antihypertensive drugs .....	26

Antihypertensive treatment in special groups	26
Hypertension in women	28
The metabolic syndrome	29
Resistant hypertension	29
Hypertensive emergencies	30
Treatment of associated risk factors	30
Patients' follow-up	30
How to improve compliance with blood pressure lowering therapy	31

---

### **Section III: Diabetic Heart Disease . . . . . 33**

---

1. Diabetes, Pre-diabetes and Cardiovascular Diseases	35
Preamble	35
Introduction	36
Definition, classification, and screening of diabetes and pre-diabetic glucose abnormalities	38
Epidemiology of diabetes, IGH, and cardiovascular risk	40
Identification of subjects at high risk for CVD or diabetes	40
Treatment to reduce cardiovascular risk	42
Management of cardiovascular disease	45
Heart failure and diabetes	48
Arrhythmias, atrial fibrillation and sudden cardiac death	48
Peripheral and cerebrovascular disease	49
Intensive care	50
Health economics and diabetes	51
References	52

---

### **Section IV: Coronary Heart Disease . . . . . 53**

---

1. Non-ST-segment Elevation Acute Coronary Syndromes	55
Introduction	55
Definitions	55
Epidemiology and natural history	56
Pathophysiology	56
Diagnosis and risk assessment	57
Treatment	59
Complications and their management	63
Special populations and conditions	64
Management strategies	66
2. Acute Myocardial Infarction in Patients Presenting with Persistent ST-Segment Elevation	69
Introduction	69
First medical contact and emergency care flow	70
Pre-hospital or early in-hospital care	71
Later in-hospital care	75
Secondary prevention	78
3. Stable Angina Pectoris	81
Introduction	81
Diagnosis and assessment	82
Treatment	86
Special diagnostic considerations: angina with "normal" coronary arteries	93
4. Percutaneous Coronary Interventions (PCI)	95
Introduction and Definitions	95
Indications for PCI	96
Adjunctive Medications for PCI	100
Adjunctive Devices for PCI	101
Drug-eluting Stents (DES)	102

<b>1.</b>	<b>Hypertrophic Cardiomyopathy . . . . .</b>	<b>107</b>
	Introduction . . . . .	107
	Genetics . . . . .	107
	Presentation . . . . .	107
	Diagnosis . . . . .	107
	Differential diagnosis . . . . .	108
	Pathophysiological features . . . . .	108
	Examination . . . . .	108
	Treatment . . . . .	108
	Medical therapy . . . . .	108
	Treatment options for drug-refractory patients . . . . .	109
	Drugs for “end stage” . . . . .	110
	Infective endocarditis prophylaxis . . . . .	110
	Pregnancy . . . . .	110
	Prevention of sudden cardiac death . . . . .	111
	Exercise recommendations . . . . .	111
	Screening . . . . .	111
	HCM in the elderly . . . . .	111

---

**Section VI: Pericardial Disease . . . . . 113**

---

<b>1.</b>	<b>Pericardial Diseases . . . . .</b>	<b>115</b>
	Introduction . . . . .	115
	Acute pericarditis . . . . .	116
	Pericardial effusion and cardiac tamponade . . . . .	119
	Constrictive pericarditis . . . . .	121
	Viral pericarditis . . . . .	123
	Bacterial pericarditis . . . . .	123
	Pericarditis in renal failure . . . . .	124
	Autoreactive pericarditis and pericardial involvement in systemic autoimmune diseases . . . . .	124
	The post-cardiac injury syndrome: postpericardiotomy syndrome . . . . .	125
	Post-infarction pericarditis . . . . .	125
	Traumatic pericardial effusion . . . . .	125
	Haemopericardium in aortic dissection . . . . .	126
	Neoplastic pericarditis . . . . .	126
	Pericardial effusion in pregnancy . . . . .	126
	Foetal pericardial effusion . . . . .	126
	Drug- and toxin-related pericardial disease . . . . .	127

---

**Section VII: Congenital Heart Disease . . . . . 129**

---

<b>1.</b>	<b>Grown Up Congenital Heart Disease . . . . .</b>	<b>131</b>
	Introduction & background . . . . .	131
	Organisation of care . . . . .	132
	Medical issues . . . . .	132
	Surgical issues . . . . .	141
	Psychosocial issues . . . . .	141
	Specific lesions . . . . .	143

2.	Neonatal Electrocardiogram .....	159
	Introduction .....	159
	Normal electrocardiogram in the newborn .....	159
	Abnormal electrocardiogram in the newborn .....	161
<hr/>		
<b>Section VIII: Pregnancy and Heart Disease .....</b>		<b>171</b>
<hr/>		
1.	Cardiovascular Disease during Pregnancy .....	173
	Introduction .....	173
	Physiological changes during pregnancy .....	173
	In general .....	174
	Congenital heart disease .....	174
	Marfan syndrome and other inherited conditions affecting the aorta .....	175
	Acquired valvular heart disease .....	175
	Cardiomyopathies .....	176
	Arrhythmias .....	176
	Hypertensive disorders .....	177
<hr/>		
<b>Section IX: Valvular Heart Disease .....</b>		<b>179</b>
<hr/>		
1.	Valvular Heart Disease .....	181
	Introduction .....	181
	Patient evaluation .....	182
	Indications for treatment in native valve diseases .....	183
	Prosthetic valves .....	190
	Management during non-cardiac surgery .....	193
	Management during pregnancy .....	193
<hr/>		
<b>Section X: Infective Endocarditis .....</b>		<b>195</b>
<hr/>		
1.	Prevention, Diagnosis and Treatment of Infective Endocarditis .....	197
	Introduction .....	197
	Classification, definitions .....	198
	Preventive measures .....	198
	Diagnosis .....	200
	Prognostic assessment at admission .....	202
	Antimicrobial therapy: principles and methods .....	203
	Indications and optimal timing of surgery in left-sided NVE .....	205
	Neurological complications .....	206
	Prosthetic valve infective endocarditis (PVE) .....	206
	Cardiac device-related infective endocarditis (CDRIE) .....	207
	Right-sided infective endocarditis .....	208
<hr/>		
<b>Section XI: Pulmonary Hypertension .....</b>		<b>209</b>
<hr/>		
1.	Pulmonary Hypertension .....	211
	Introduction .....	211
	Definitions .....	212
	Clinical classification of pulmonary hypertension .....	212
	Pulmonary arterial hypertension (Group 1) .....	213
	Pulmonary veno-occlusive disease and pulmonary capillary haemangiomas (Group 1') .....	224
	Pulmonary hypertension due to left heart disease (Group 2) .....	224
	Pulmonary hypertension due to lung diseases and/or hypoxaemia (Group 3) .....	224
	Chronic thromboembolic pulmonary hypertension (Group 4) .....	225
	Definition of pulmonary arterial hypertension referral centre .....	225

1.	Supraventricular Arrhythmias (SVA) . . . . .	229
	Introduction . . . . .	229
	General evaluation and management . . . . .	230
	Specific arrhythmias . . . . .	231
	References . . . . .	246
2.	Atrial Fibrillation (AF) . . . . .	247
	Introduction . . . . .	247
	Classification of AF . . . . .	248
	Epidemiology and prognosis . . . . .	249
	Clinical evaluation . . . . .	249
	Proposed management strategies . . . . .	249
	Recommendations . . . . .	259
3.	Syncope . . . . .	267
	Definition, classification and pathophysiology, epidemiology, prognosis and impact on quality of life . . . . .	268
	Initial evaluation, risk stratification and diagnosis . . . . .	269
	Treatment . . . . .	274
	Special issues . . . . .	276
	Syncope management unit . . . . .	277
4.	Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death . . . . .	279
	Introduction . . . . .	279
	Incidence of Sudden Cardiac Death . . . . .	282
	Clinical Presentations of Patients with Ventricular Arrhythmias and Sudden Cardiac Death . . . . .	282
	General Evaluation of Patients with Documented or Suspected Ventricular Arrhythmias . . . . .	283
	Therapies for Ventricular Arrhythmias . . . . .	285
	Acute Management of Specific Arrhythmias . . . . .	285
	Ventricular Arrhythmia and Sudden Cardiac Death Related to Specific Pathology . . . . .	288
	Ventricular Arrhythmias Associated with Cardiomyopathies . . . . .	290
	Heart Failure . . . . .	292
	Genetic Arrhythmia Syndromes . . . . .	293
	Ventricular Arrhythmias and Sudden Cardiac Death Related to Specific Populations . . . . .	294
5.	Cardiac Pacing and Cardiac Resynchronization Therapy . . . . .	297
	Introduction . . . . .	297
	Pacing in arrhythmias . . . . .	298
	Pacing for specific conditions . . . . .	303
	Cardiac resynchronization therapy in patients with heart failure . . . . .	303

1.	Universal Definition of Myocardial Infarction . . . . .	307
	Definition of myocardial infarction . . . . .	308
	Classification of myocardial infarction . . . . .	309
	Cardiac biomarkers for detecting myocardial infarction . . . . .	309
	Elevations of troponin in the absence of overt ischaemic heart disease . . . . .	309
	Electrocardiographic detection of myocardial infarction . . . . .	310
	Imaging techniques for detection of myocardial infarction . . . . .	311
	Myocardial infarction associated with interventions . . . . .	311

---

**Section XIV: Pulmonary Embolism . . . . . 313**

---

1.	Acute Pulmonary Embolism . . . . .	315
	Introduction . . . . .	315
	Predisposing factors, symptoms and signs of PE . . . . .	316
	Initial risk stratification . . . . .	317
	Assessment of clinical probability . . . . .	317
	Diagnostic assessment . . . . .	318
	Comprehensive risk stratification . . . . .	319
	Initial treatment . . . . .	321
	Long term treatment . . . . .	323
	Venous filters . . . . .	323
	Specific situations . . . . .	323
	Appendix . . . . .	324

---

**Section XV: Heart Failure . . . . . 325**

---

1.	Acute and Chronic Heart Failure . . . . .	327
	Introduction . . . . .	327
	Definition & Diagnosis . . . . .	328
	Diagnostic Techniques . . . . .	330
	Non-pharmacological Management . . . . .	335
	Pharmacological Therapy . . . . .	335
	Devices & Surgery . . . . .	339
	Arrhythmias in Heart Failure . . . . .	341
	Comorbidities & Special Populations . . . . .	342
	Acute Heart Failure . . . . .	343
	Implementation & Delivery of Care . . . . .	351

---

**Section XVI: Cardiac Consult . . . . . 353**

---

1.	Preoperative Cardiac Risk Assessment and Perioperative Cardiac Management in Non-Cardiac Surgery . . . . .	355
	Introduction . . . . .	355
	Pathophysiology of perioperative myocardial infarction . . . . .	356
	Practical preoperative cardiac risk assessment . . . . .	356
	Preoperative evaluation . . . . .	358
	Risk reduction strategies . . . . .	359
	Specific diseases . . . . .	362
	Perioperative monitoring . . . . .	363
	References . . . . .	368

Glossary . . . . .	369
--------------------	-----

Index . . . . .	375
-----------------	-----

ESC website link . . . . .	392
----------------------------	-----